Tandem Diabetes Care
TNDM
16.11
+0.44
+2.78%
Tandem Diabetes Care
US · TNDM
#3179 by market cap
16.11
+0.44
+2.78%
Live - 5344 symbols - heartbeat 140s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -0.03, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.93% YoY
Margins
- Gross margin
- 53.81%
- Operating margin
- -16.49%
- Net margin
- -20.17%
Key ratios & quality
- Enterprise valuei
- 1.16B
- Altman Z-Scorei
- -0.03
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 183.87M | 362.31M | 498.83M | 702.80M | 801.22M | 747.72M | 940.20M | 1.01B |
| Gross profit | 89.82M | 194.21M | 260.52M | 376.22M | 412.99M | 367.69M | 489.57M | 546.01M |
| Selling & admin expenses | 105.23M | 165.74M | 204.90M | 261.51M | 335.68M | 352.50M | 389.82M | 444.99M |
| Research & development | 29.23M | 45.20M | 63.57M | 92.05M | 170.15M | 248.42M | 198.88M | 268.33M |
| Operating profit | -44.63M | -16.72M | -7.96M | 22.65M | -92.85M | -233.23M | -99.13M | -167.31M |
| Pretax profit | -122.56M | -24.60M | -36.28M | 15.90M | -92.85M | -220.25M | -91.87M | -200.27M |
| Tax | 51.00K | 149.00K | -1.90M | 335.00K | 1.74M | 2.36M | 4.16M | 4.44M |
| Net profit | -122.61M | -24.75M | -34.38M | 15.57M | -94.59M | -222.61M | -96.03M | -204.71M |
| Basic EPS | -3 | 0 | -1 | 0 | -1 | -3 | -1 | -3 |
| Diluted EPS | -2.55 | -0.42 | -0.56 | 0.24 | -1.47 | -3.43 | -1.47 | -3.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 234.42M | 240.68M | 249.25M | 290.38M | 247.22M | 254.56M |
| Gross profit | 118.41M | 125.86M | 134.29M | 167.46M | 136.79M | 144.78M |
| Selling & admin expenses | 113.85M | 109.60M | 108.44M | 113.10M | 108.19M | 111.64M |
| Research & development | 125.43M | 48.12M | 48.72M | 46.07M | 46.04M | 46.93M |
| Operating profit | -120.88M | -31.86M | -22.86M | 8.29M | -17.43M | -13.79M |
| Pretax profit | -122.09M | -57.72M | -25.14M | 4.68M | -19.88M | -20.66M |
| Tax | 8.47M | -5.32M | -3.98M | 5.27M | 516.00K | 510.00K |
| Net profit | -130.56M | -52.40M | -21.17M | -589.00K | -20.39M | -21.17M |
| Basic EPS | -2 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -1.97 | -0.78 | -0.31 | -0.01 | -0.30 | -0.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 187.89M | 276.14M | 637.24M | 811.52M | 849.98M | 747.99M | 724.49M | 618.14M |
| Cash & ST investments | 129.03M | 176.46M | 484.94M | 623.81M | 616.90M | 467.91M | 438.33M | 292.67M |
| Inventory | 19.90M | 49.07M | 63.72M | 68.55M | 111.12M | 157.94M | 149.61M | 128.77M |
| Total assets | 206.29M | 326.11M | 716.42M | 905.14M | 1.05B | 952.66M | 967.66M | 881.11M |
| Total current liabilities | 66.29M | 99.40M | 103.85M | 131.86M | 165.29M | 195.26M | 247.05M | 242.72M |
| Short-term debt | -- | 6.32M | 9.42M | 9.28M | 13.12M | 17.06M | 58.88M | 19.47M |
| Long-term debt | -- | -- | 202.98M | 281.47M | 283.23M | 285.04M | 308.27M | 310.04M |
| Total liabilities | 75,019,000.00 | 131,131,000.00 | 350,110,000.00 | 472,025,000.00 | 612,838,000.00 | 639,026,000.00 | 704,560,000.00 | 725,942,000.00 |
| Total equity | 131.28M | 194.98M | 366.31M | 433.11M | 439.95M | 313.63M | 263.10M | 155.17M |
| Retained earnings | -600.08M | -624.83M | -659.21M | -634.60M | -729.19M | -951.80M | -1.05B | -1.25B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 663.44M | 614.82M | 616.94M | 618.14M | 887.10M | 804.64M |
| Cash & ST investments | 368.63M | 315.36M | 319.11M | 292.67M | 570.26M | 456.00M |
| Inventory | 141.17M | 142.57M | 137.28M | 128.77M | 126.40M | 135.11M |
| Total assets | 922.14M | 875.74M | 874.65M | 881.11M | 1.15B | 1.15B |
| Total current liabilities | 288.18M | 251.69M | 252.54M | 242.72M | 247.96M | 253.01M |
| Short-term debt | 61.45M | 19.89M | 21.34M | 19.47M | 20.11M | 20.27M |
| Long-term debt | 308.71M | 309.15M | 309.59M | 310.04M | 601.77M | 602.58M |
| Total liabilities | 766,851,000.00 | 742,453,000.00 | 741,688,000.00 | 725,942,000.00 | 1,020,991,000.00 | 1,023,814,000.00 |
| Total equity | 155.29M | 133.28M | 132.97M | 155.17M | 132.40M | 130.39M |
| Retained earnings | -1.18B | -1.23B | -1.25B | -1.25B | -1.27B | -1.29B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -8.32M | 41.91M | 24.67M | 111.36M | 50.46M | -31.81M | 24.23M | -9.72M |
| Depreciation & amortization | 5.82M | 6.07M | 10.45M | 13.85M | 14.33M | 15.72M | 16.61M | 17.67M |
| Free cash flow | -11.31M | 22.37M | -7.63M | 87.85M | 16.37M | -128.11M | 4.99M | -108.26M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 172.93M | -- | -- | -- | 0 | 0 | -30.00M | 0 |
| Ending cash balance | 41.83M | 51.18M | 94.61M | 71.18M | 172.52M | 58.87M | 69.23M | 90.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -18.28M | -9.50M | 8.26M | 9.79M | 11.05M | -34.63M |
| Depreciation & amortization | 4.31M | 4.37M | 4.49M | 4.50M | 4.50M | 4.47M |
| Free cash flow | -64.71M | -15.70M | 4.17M | -32.02M | 4.79M | -38.68M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 53.57M | 64.11M | 91.95M | 90.63M | 179.33M | 62.82M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -240.11 | -15.17 | -12.25 | 3.89 | -21.67 | -59.08 | -33.30 | -97.88 |
| ROA %i | -81.30 | -9.30 | -6.60 | 1.92 | -9.66 | -22.20 | -10.00 | -22.15 |
| ROIC %i | -231.36 | -14.76 | -6.01 | 2.85 | -11.94 | -29.49 | -14.45 | -31.00 |
| 5-year avg ROE %i | -- | -- | -- | -- | -57.06 | -20.86 | -24.48 | -41.61 |
| EBIT margin %i | -62.53 | -6.77 | -4.84 | 2.88 | -11.05 | -28.38 | -9.19 | -19.14 |
| FCF / sales %i | -- | 6.17 | -- | 12.50 | 0.94 | -- | 0.53 | -- |
| Current ratioi | 2.83 | 2.78 | 6.14 | 6.15 | 5.14 | 3.83 | 2.93 | 2.55 |
| Quick ratioi | 2.48 | 2.24 | 5.46 | 5.57 | 4.43 | 2.94 | 2.24 | 1.89 |
| Debt / assetsi | 0.00 | 6.25 | 31.87 | 34.76 | 39.88 | 43.63 | 48.94 | 50.44 |
| LT debt / equityi | -- | 7.21 | 59.76 | 70.51 | 92.46 | 127.09 | 157.62 | 273.90 |
| Interest coveragei | -15.16 | -314.44 | -1.99 | 4.69 | -20.53 | -26.26 | -15.68 | -32.12 |
| Revenue CAGR (3Y) %i | 36.15 | 62.62 | 66.74 | 56.35 | 30.28 | 14.44 | 10.19 | 8.19 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -9.88 | -- | -61.55 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -92.31 | -111.91 | -109.73 | -97.88 | -65.73 | -48.03 |
| ROA %i | -19.74 | -22.66 | -22.20 | -22.15 | -9.11 | -6.24 |
| ROIC %i | -28.18 | -32.73 | -32.12 | -31.00 | -12.76 | -9.01 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -17.19 | -19.65 | -19.78 | -19.14 | -8.93 | -5.19 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.30 | 2.44 | 2.44 | 2.55 | 3.58 | 3.18 |
| Quick ratioi | 1.72 | 1.76 | 1.76 | 1.89 | 2.87 | 2.44 |
| Debt / assetsi | 53.48 | 51.27 | 51.37 | 50.44 | 63.70 | 64.05 |
| LT debt / equityi | 278.03 | 321.96 | 321.85 | 273.90 | 539.74 | 551.42 |
| Interest coveragei | -31.09 | -35.24 | -34.42 | -32.12 | -14.52 | -7.80 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Supplies and other is the largest reported line at 54.96% of revenue, across 2 reported segments.
- Pump follows at 45.04%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Supplies and other54.96%
Pump45.04%
Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Tandem Diabetes Care discussion 0 comments